Martin Rogelio Salazar
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Martin Rogelio Salazar has a total of 216 co-authors. Here are the top co-authors by number of shared publications:
- Walter Gaston Espeche
Unidad de Enfermedades Cardiometabólicas, Servicio de Clínica Médica, Hospital Gral. San Martín, La Plata, Argentina
20 shared publications - Julian Minetto
Cardiometabolic Diseases Unit, San Martín Hospital of La Plata, Buenos Aires, Argentina
17 shared publications - Carlos Enrique Leiva Sisnieguez
Unidad de Enfermedades Cardiometabólicas, Servicio de Clínica Médica, Hospital Gral. San Martín, La Plata, Argentina
16 shared publications Horacio A. Carbajal
Facultad de Ciencias Médicas, UNLP, La Plata, Argentina
13 shared publicationsEduardo Balbín
Facultad de Ciencias Médicas, UNLP, La Plata, Argentina
11 shared publicationsWalter G. Espeche
Facultad de Ciencias Médicas. Universidad Nacional de La Plata, La Plata, Argentina
10 shared publications
Latest Publications
- 30 September 2026
- Published by Springer Nature in Journal of Human Hypertension
- p. 1-3
Apparent versus true resistant hypertension in a real-world argentine cohort
- 30 September 2026
- Published by Springer Nature in Journal of Human Hypertension
- p. 1-3
Apparent versus true resistant hypertension in a real-world argentine cohort
- 25 September 2026
- Published by Springer Nature in Journal of Human Hypertension
- p. 1-3
Association between the triglyceride/high-density lipoprotein cholesterol ratio and isolated nocturnal hypertension
Isolated nocturnal hypertension is associated with increased cardiovascular risk, but its relationship with insulin resistance remains uncertain. In this study of 1623 patients undergoing ambulatory blood pressure monitoring, the triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio was higher in patients with isolated nocturnal hypertension than in normotensive individuals; however, this association was no longer significant after adjustment for cardiometabolic risk factors. These findings suggest that insulin resistance reflects the adverse metabolic profile accompanying isolated nocturnal hypertension rather than an independent determinant of this phenotype.
- 25 September 2026
- Published by Springer Nature in Journal of Human Hypertension
- p. 1-3
Association between the triglyceride/high-density lipoprotein cholesterol ratio and isolated nocturnal hypertension
Isolated nocturnal hypertension is associated with increased cardiovascular risk, but its relationship with insulin resistance remains uncertain. In this study of 1623 patients undergoing ambulatory blood pressure monitoring, the triglyceride-to-high-density lipoprotein cholesterol (TG/HDL-C) ratio was higher in patients with isolated nocturnal hypertension than in normotensive individuals; however, this association was no longer significant after adjustment for cardiometabolic risk factors. These findings suggest that insulin resistance reflects the adverse metabolic profile accompanying isolated nocturnal hypertension rather than an independent determinant of this phenotype.
- 29 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Development and external validation of the SCORE2 models in Latin America and the Caribbean (SCORE2-LAC) to estimate 10-year cardiovascular disease risk
Background and Aims: Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods: Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results: In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions: The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC.
- 29 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Development and external validation of the SCORE2 models in Latin America and the Caribbean (SCORE2-LAC) to estimate 10-year cardiovascular disease risk
Background and Aims: Despite the high burden of cardiovascular disease (CVD) in Latin America and the Caribbean (LAC), risk prediction models adapted for use in LAC populations remain limited. The aim of this study was to recalibrate the Systematic COronary Risk Evaluation 2 (SCORE2) risk models for estimating 10-year CVD risk in individuals without prior CVD or diabetes mellitus in LAC, resulting in the SCORE2 Latin America and the Caribbean (SCORE2-LAC) models. Methods: Sex-specific, competing risk-adjusted SCORE2 models were recalibrated to contemporary CVD incidence across four risk regions, defined by country-level age- and sex-standardized CVD mortality rates, using region-specific risk factor distributions. Cardiovascular disease incidence was estimated from CVD mortality data and ratios of the total first-to-fatal CVD events, derived from 40 237 152 individuals (1 261 329 CVD events). External validation included 132 512 individuals without prior CVD or diabetes from 11 cohorts across seven countries (3938 CVD events). Discrimination was assessed using Harrell’s C-index. Results: In the external validation datasets, the pooled C-index of SCORE2-LAC was .740 [95% confidence interval (CI) .716–.763], with cohort-specific C-indices ranging from .674 (95% CI .588–.761) to .789 (95% CI .747–.831). Estimated CVD risk varied several-fold across the four LAC risk regions. For a 50-year-old non-smoker with a systolic blood pressure of 140 mmHg, total cholesterol of 213 mg/dL (5.5 mmol/L), and HDL cholesterol of 50 mg/dL (1.3 mmol/L), the predicted risk ranged from 3% in low-risk countries to 10% in very-high-risk countries for women, and from 4% to 10% for men. Conclusions: The SCORE2-LAC models provide region-specific contemporary estimates of 10-year CVD risk in apparently healthy individuals, enabling identification of individuals at high CVD risk across LAC.
- 7 July 2026
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (8) , 674-676
Nocturnal blood pressure and the risk of preeclampsia: an overlooked link
- 7 July 2026
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (8) , 674-676
Nocturnal blood pressure and the risk of preeclampsia: an overlooked link
- 27 April 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (9) , 1061-1066
ADAM17 expression in ACEI/ARB-treated patients with hypertension was comparable to that observed in patients without hypertension
Background: ADAM17 (A disintegrin and metalloproteinase 17) contributes to angiotensin-converting enzyme (ACE) 2 shedding in response to angiotensin II–AT1 receptor signaling, potentially shifting the renin–angiotensin system toward its pressor arm. We investigated whether ACE inhibitor (ACEI) or AT1 receptor blocker (ARB) therapy modulates ADAM17 expression. Methods: ADAM17 protein expression was evaluated by immunohistochemistry in alveolar type II pneumocytes of lung parenchymal samples from untreated control patients (n = 20) and patients treated with ACEI (n = 21) or ARB (n = 17; total ACEI/ARB-treated patients = 38). Results: There were no significant differences in the proportion of ADAM17-expressing type II pneumocytes between patients without hypertension and ACEI/ARB-treated patients with hypertension (56.1 ± 4.3% vs. 45.8 ± 3.1%, respectively). Similarly, no differences were observed according to smoking status (50.6 ± 4.1% in never smokers, 48.4 ± 4.0% in current smokers, and 50.8 ± 6.8% in former smokers) or sex (49.7 ± 4.2% in women vs. 49.1 ± 3.3% in men). In contrast, a significant age-related decline in the proportion of ADAM17-expressing type II pneumocytes was observed (56.2 ± 3.5% in patients <60 years vs. 43.0 ± 3.5% in patients ≥60 years; P = .005). Conclusions: These findings suggest that ACEI/ARB therapy, while targeting the pressor axis of the RAS, maintains ADAM17 expression at levels comparable to those in patients without hypertension. ACEI/ARB therapy may represent a potential strategy for the treatment of ADAM17-mediated cardiovascular, pulmonary, and inflammatory diseases.
- 27 April 2026
- Published by Oxford University Press (OUP) in American Journal of Hypertension
- Vol. 39 (9) , 1061-1066
ADAM17 expression in ACEI/ARB-treated patients with hypertension was comparable to that observed in patients without hypertension
Background: ADAM17 (A disintegrin and metalloproteinase 17) contributes to angiotensin-converting enzyme (ACE) 2 shedding in response to angiotensin II–AT1 receptor signaling, potentially shifting the renin–angiotensin system toward its pressor arm. We investigated whether ACE inhibitor (ACEI) or AT1 receptor blocker (ARB) therapy modulates ADAM17 expression. Methods: ADAM17 protein expression was evaluated by immunohistochemistry in alveolar type II pneumocytes of lung parenchymal samples from untreated control patients (n = 20) and patients treated with ACEI (n = 21) or ARB (n = 17; total ACEI/ARB-treated patients = 38). Results: There were no significant differences in the proportion of ADAM17-expressing type II pneumocytes between patients without hypertension and ACEI/ARB-treated patients with hypertension (56.1 ± 4.3% vs. 45.8 ± 3.1%, respectively). Similarly, no differences were observed according to smoking status (50.6 ± 4.1% in never smokers, 48.4 ± 4.0% in current smokers, and 50.8 ± 6.8% in former smokers) or sex (49.7 ± 4.2% in women vs. 49.1 ± 3.3% in men). In contrast, a significant age-related decline in the proportion of ADAM17-expressing type II pneumocytes was observed (56.2 ± 3.5% in patients <60 years vs. 43.0 ± 3.5% in patients ≥60 years; P = .005). Conclusions: These findings suggest that ACEI/ARB therapy, while targeting the pressor axis of the RAS, maintains ADAM17 expression at levels comparable to those in patients without hypertension. ACEI/ARB therapy may represent a potential strategy for the treatment of ADAM17-mediated cardiovascular, pulmonary, and inflammatory diseases.
- 2 February 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 43, 101416
Changes in ambulatory blood pressure monitoring during the first half of pregnancy to predict preeclampsia
- 2 February 2026
- Published by Elsevier in Pregnancy Hypertension
- Vol. 43, 101416
Changes in ambulatory blood pressure monitoring during the first half of pregnancy to predict preeclampsia
- Open Access
- 2 December 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (2) , 96-102
Isolated nocturnal hypertension and its association with sleep duration and quality
Nocturnal blood pressure (BP) is associated with cardiovascular events independently of daytime BP. Isolated nocturnal hypertension (INH), defined by elevated nocturnal BP with normal daytime BP, increases cardiovascular risk. However, its underlying; mechanisms remain unclear. This study aims to assess the association between nocturnal BP and INH with sleep quality and duration. This cross-sectional study analyzed 2297 individuals (57% women, 49.5 ± 15 years) using ambulatory blood pressure monitoring (ABPM) to evaluate the relationship between INH and sleep quality. Individuals with secondary hypertension and sleep disorders were excluded. Sleep quality and duration were primarily assessed using the Pittsburgh Sleep Quality Index (PSQI) and the STOP-BANG score. Results showed that 64% had poor sleep quality (PSQI > 5), and 18.7% slept less than 6 h. No significant differences in sleep quality were found among hypertensive phenotypes. INH was associated with older age, diabetes, and waist circumference; however, sleep quality and duration were not independent factors in its development. Nonetheless, nocturnal BP exhibited a slight association with sleep quality and disturbances of mild clinical significance.
- 2 December 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (2) , 96-102
Open AccessIsolated nocturnal hypertension and its association with sleep duration and quality
Nocturnal blood pressure (BP) is associated with cardiovascular events independently of daytime BP. Isolated nocturnal hypertension (INH), defined by elevated nocturnal BP with normal daytime BP, increases cardiovascular risk. However, its underlying; mechanisms remain unclear. This study aims to assess the association between nocturnal BP and INH with sleep quality and duration. This cross-sectional study analyzed 2297 individuals (57% women, 49.5 ± 15 years) using ambulatory blood pressure monitoring (ABPM) to evaluate the relationship between INH and sleep quality. Individuals with secondary hypertension and sleep disorders were excluded. Sleep quality and duration were primarily assessed using the Pittsburgh Sleep Quality Index (PSQI) and the STOP-BANG score. Results showed that 64% had poor sleep quality (PSQI > 5), and 18.7% slept less than 6 h. No significant differences in sleep quality were found among hypertensive phenotypes. INH was associated with older age, diabetes, and waist circumference; however, sleep quality and duration were not independent factors in its development. Nonetheless, nocturnal BP exhibited a slight association with sleep quality and disturbances of mild clinical significance.
- 21 November 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (3) , 158-162
Pulse wave velocity in high-risk pregnant women who subsequently developed early- and late-onset preeclampsia
We conducted a prospective study in consecutive high-risk pregnant women with 8 to 34 weeks of gestation to evaluate the relationship between PWV and the subsequent development of early- and late- onset preeclampsia (PE). The cohort was divided in high PWV (defined by the top tertile) and normal PWV (the remaining two tertiles). PE were classified as late-onset PE and early- onset PE using a cut-point of 34 weeks of gestation. The risk of women with high PWV for early- and late-onset PE was compared with women with normal PWV using multinomial regression. Two hundred and sixty-three high-risk pregnant women (mean age 30 ± 7 years, with 26 ± 7 weeks of gestation at the evaluation) were included in the study; 7.4%, 22.6%, 1.2%, 3.1% and 0.8% had antecedents of diabetes, chronic hypertension, chronic renal disease, collagen diseases and antiphospholipid syndrome, respectively. In previous pregnancies, 11.3% had had gestational diabetes and 22,6% hypertensive disorders of pregnancy. Forty-six pregnant women (17.9%) developed PE, of which 31 (12.1%) were late-onset and 15 (5.8%) early-onset. Women with high PWV more frequently developed early-onset than late-onset PE (14.0% vs 11.8% p = 0.509). Unadjusted and adjusted OR for early-onset PE were 9.61 (95%CI 2.62-35.25) and 7.13 (1.89-26.71), respectively. In conclusion, in high-risk pregnant women, a high PWV value was related with ~7 times more risk for development of early-onset PE.
- 21 November 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 40 (3) , 158-162
Pulse wave velocity in high-risk pregnant women who subsequently developed early- and late-onset preeclampsia
We conducted a prospective study in consecutive high-risk pregnant women with 8 to 34 weeks of gestation to evaluate the relationship between PWV and the subsequent development of early- and late- onset preeclampsia (PE). The cohort was divided in high PWV (defined by the top tertile) and normal PWV (the remaining two tertiles). PE were classified as late-onset PE and early- onset PE using a cut-point of 34 weeks of gestation. The risk of women with high PWV for early- and late-onset PE was compared with women with normal PWV using multinomial regression. Two hundred and sixty-three high-risk pregnant women (mean age 30 ± 7 years, with 26 ± 7 weeks of gestation at the evaluation) were included in the study; 7.4%, 22.6%, 1.2%, 3.1% and 0.8% had antecedents of diabetes, chronic hypertension, chronic renal disease, collagen diseases and antiphospholipid syndrome, respectively. In previous pregnancies, 11.3% had had gestational diabetes and 22,6% hypertensive disorders of pregnancy. Forty-six pregnant women (17.9%) developed PE, of which 31 (12.1%) were late-onset and 15 (5.8%) early-onset. Women with high PWV more frequently developed early-onset than late-onset PE (14.0% vs 11.8% p = 0.509). Unadjusted and adjusted OR for early-onset PE were 9.61 (95%CI 2.62-35.25) and 7.13 (1.89-26.71), respectively. In conclusion, in high-risk pregnant women, a high PWV value was related with ~7 times more risk for development of early-onset PE.
- 9 July 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 39 (8) , 541-548
Nocturnal systolic and diastolic blood pressure across gestational periods and the risk of preeclampsia
To investigate the relationship between blood pressure (BP) components (daytime vs. nocturnal BP and systolic vs. diastolic BP) and preeclampsia (PE) across gestational stages. We conducted a historical cohort study involving 1363 high-risk pregnant women (mean age, 30 ± 7 years). Ambulatory BP monitoring (ABPM) was performed at 12–19 weeks (n = 389), 20–27 weeks (n = 798), and 28–36 weeks (n = 1176); 59.9, 25.0, and 15.1% of the participants underwent one, two, and three ABPM evaluations, respectively. PE occurred in 15.4, 18.9, and 20.2% of the women evaluated at 12–19, 20–27, and 28–36 weeks, respectively. In the second half of pregnancy, sustained (daytime and nighttime) and isolated nocturnal hypertension were strong predictors of PE. Conversely, before the 20th week of gestation, only sustained hypertension (but not isolated nocturnal hypertension) increased PE risk, with lower odds ratios (ORs). Moreover, the areas under the curve (AUCs) for all ABPM components increased markedly after the 20th week of gestation. In late pregnancy, systolic and diastolic ABPM levels as well as all forms of nocturnal hypertension (isolated systolic, isolated diastolic, and combined systodiastolic) were significantly associated with PE risk, with ORs remaining significant after adjusting for daytime ABPM and maternal covariates. Patients with systodiastolic nocturnal hypertension had the highest risk. Conversely, neither daytime hypertension nor daytime ABPM levels remained statistically significant after adjusting for nocturnal ABPM levels. In conclusion, the association between PE and systolic, diastolic, and systodiastolic nocturnal hypertension emerges in the second half of pregnancy, suggesting a relationship with abnormal placentation.
- 9 July 2025
- Published by Springer Nature in Journal of Human Hypertension
- Vol. 39 (8) , 541-548
Nocturnal systolic and diastolic blood pressure across gestational periods and the risk of preeclampsia
To investigate the relationship between blood pressure (BP) components (daytime vs. nocturnal BP and systolic vs. diastolic BP) and preeclampsia (PE) across gestational stages. We conducted a historical cohort study involving 1363 high-risk pregnant women (mean age, 30 ± 7 years). Ambulatory BP monitoring (ABPM) was performed at 12–19 weeks (n = 389), 20–27 weeks (n = 798), and 28–36 weeks (n = 1176); 59.9, 25.0, and 15.1% of the participants underwent one, two, and three ABPM evaluations, respectively. PE occurred in 15.4, 18.9, and 20.2% of the women evaluated at 12–19, 20–27, and 28–36 weeks, respectively. In the second half of pregnancy, sustained (daytime and nighttime) and isolated nocturnal hypertension were strong predictors of PE. Conversely, before the 20th week of gestation, only sustained hypertension (but not isolated nocturnal hypertension) increased PE risk, with lower odds ratios (ORs). Moreover, the areas under the curve (AUCs) for all ABPM components increased markedly after the 20th week of gestation. In late pregnancy, systolic and diastolic ABPM levels as well as all forms of nocturnal hypertension (isolated systolic, isolated diastolic, and combined systodiastolic) were significantly associated with PE risk, with ORs remaining significant after adjusting for daytime ABPM and maternal covariates. Patients with systodiastolic nocturnal hypertension had the highest risk. Conversely, neither daytime hypertension nor daytime ABPM levels remained statistically significant after adjusting for nocturnal ABPM levels. In conclusion, the association between PE and systolic, diastolic, and systodiastolic nocturnal hypertension emerges in the second half of pregnancy, suggesting a relationship with abnormal placentation.
- Open Access
- 31 March 2025
- Published by Springer Nature in Research Square
Nocturnal Systolic and Diastolic Blood Pressure Across Gestational Periods and the Risk of Preeclampsia
To investigate the relationship between blood pressure (BP) components (daytime vs. nocturnal BP and systolic vs. diastolic BP) and preeclampsia (PE) across gestational stages. We conducted a historical cohort study involving 1,363 high-risk pregnant women (mean age, 30 ± 7 years). Ambulatory BP monitoring (ABPM) was performed at 12–19 weeks (n = 389), 20–27 weeks (n = 798), and 28–36 weeks (n = 1,176); 59.9%, 25.0%, and 15.1% of the participants underwent one, two, and three ABPM evaluations, respectively. PE occurred in 15.4%, 18.9%, and 20.2% of the women evaluated at 12–19, 20–27, and 28–36 weeks, respectively. In the second half of pregnancy, sustained (daytime and nighttime) and isolated nocturnal hypertension were strong predictors of PE. Conversely, before the 20th week of gestation, only sustained hypertension (but not isolated nocturnal hypertension) increased PE risk, with lower odds ratios (ORs). Moreover, the areas under the curve (AUCs) for all ABPM components increased markedly after the 20th week of gestation. In late pregnancy, systolic and diastolic ABPM levels as well as all forms of nocturnal hypertension (isolated systolic, isolated diastolic, and combined systodiastolic) were significantly associated with PE risk, with ORs remaining significant after adjusting for daytime ABPM and maternal covariates. Patients with systodiastolic nocturnal hypertension had the highest risk. Conversely, neither daytime hypertension nor daytime ABPM levels remained statistically significant after adjusting for nocturnal ABPM levels. In conclusion, the association between PE and systolic, diastolic, and systodiastolic nocturnal hypertension emerges in the second half of pregnancy, suggesting a relationship with abnormal placentation.
- 31 March 2025
- Published by Springer Nature in Research Square
Open AccessNocturnal Systolic and Diastolic Blood Pressure Across Gestational Periods and the Risk of Preeclampsia
To investigate the relationship between blood pressure (BP) components (daytime vs. nocturnal BP and systolic vs. diastolic BP) and preeclampsia (PE) across gestational stages. We conducted a historical cohort study involving 1,363 high-risk pregnant women (mean age, 30 ± 7 years). Ambulatory BP monitoring (ABPM) was performed at 12–19 weeks (n = 389), 20–27 weeks (n = 798), and 28–36 weeks (n = 1,176); 59.9%, 25.0%, and 15.1% of the participants underwent one, two, and three ABPM evaluations, respectively. PE occurred in 15.4%, 18.9%, and 20.2% of the women evaluated at 12–19, 20–27, and 28–36 weeks, respectively. In the second half of pregnancy, sustained (daytime and nighttime) and isolated nocturnal hypertension were strong predictors of PE. Conversely, before the 20th week of gestation, only sustained hypertension (but not isolated nocturnal hypertension) increased PE risk, with lower odds ratios (ORs). Moreover, the areas under the curve (AUCs) for all ABPM components increased markedly after the 20th week of gestation. In late pregnancy, systolic and diastolic ABPM levels as well as all forms of nocturnal hypertension (isolated systolic, isolated diastolic, and combined systodiastolic) were significantly associated with PE risk, with ORs remaining significant after adjusting for daytime ABPM and maternal covariates. Patients with systodiastolic nocturnal hypertension had the highest risk. Conversely, neither daytime hypertension nor daytime ABPM levels remained statistically significant after adjusting for nocturnal ABPM levels. In conclusion, the association between PE and systolic, diastolic, and systodiastolic nocturnal hypertension emerges in the second half of pregnancy, suggesting a relationship with abnormal placentation.